234 related articles for article (PubMed ID: 30679329)
1. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Tarantelli C; Zhang L; Curti E; Gaudio E; Spriano F; Priebe V; Cascione L; Arribas AJ; Zucca E; Rossi D; Stathis A; Bertoni F
Haematologica; 2019 Jul; 104(7):e307-e309. PubMed ID: 30679329
[No Abstract] [Full Text] [Related]
2. Zanubrutinib: First Approval.
Syed YY
Drugs; 2020 Jan; 80(1):91-97. PubMed ID: 31933167
[TBL] [Abstract][Full Text] [Related]
3. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
7. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
Zhao X; Bodo J; Sun D; Durkin L; Lin J; Smith MR; Hsi ED
Br J Haematol; 2015 Mar; 168(5):765-8. PubMed ID: 25284608
[No Abstract] [Full Text] [Related]
8. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract][Full Text] [Related]
9. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Jiang H; Lwin T; Zhao X; Ren Y; Li G; Moscinski L; Shah B; Tao J
Br J Haematol; 2019 Jan; 184(2):298-302. PubMed ID: 29383700
[No Abstract] [Full Text] [Related]
11. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Hanna KS; Campbell M; Husak A; Sturm S
J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
[TBL] [Abstract][Full Text] [Related]
12. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
13. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Roulin L; Haioun C; Lemonnier F
Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
[No Abstract] [Full Text] [Related]
14. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Furtado M; Wang ML; Munneke B; McGreivy J; Beaupre DM; Rule S
Br J Haematol; 2015 Jul; 170(1):131-4. PubMed ID: 25559624
[No Abstract] [Full Text] [Related]
15. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Bond DA; Maddocks KJ
Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Soumerai JD; Diefenbach CS; Jagadeesh D; Asch A; Kumar A; Tsai ML; Jandl TA; Lossos IS; Kenkre VP; Awan F; Novotny W; Huang J; Miao L; Rajagopalan P; Ghalie RG; Zelenetz AD
Br J Haematol; 2024 May; 204(5):1762-1770. PubMed ID: 38500476
[TBL] [Abstract][Full Text] [Related]
18. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Gaudio E; Tarantelli C; Kwee I; Barassi C; Bernasconi E; Rinaldi A; Ponzoni M; Cascione L; Targa A; Stathis A; Goodstal S; Zucca E; Bertoni F
Ann Oncol; 2016 Jun; 27(6):1123-1128. PubMed ID: 26961147
[TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
20. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
